J
Joseph D. Rosenblatt
Researcher at University of Miami
Publications - 204
Citations - 12518
Joseph D. Rosenblatt is an academic researcher from University of Miami. The author has contributed to research in topics: Brentuximab vedotin & Antigen. The author has an hindex of 50, co-authored 201 publications receiving 11748 citations. Previous affiliations of Joseph D. Rosenblatt include University of Maryland, Baltimore & Cedars-Sinai Medical Center.
Papers
More filters
Journal ArticleDOI
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
Anas Younes,Ajay K. Gopal,Scott E. Smith,Stephen M. Ansell,Joseph D. Rosenblatt,Kerry J. Savage,Radhakrishnan Ramchandren,Nancy L. Bartlett,Bruce D. Cheson,Sven de Vos,Andres Forero-Torres,Craig H. Moskowitz,Joseph M. Connors,Andreas Engert,Emily K. Larsen,Dana A. Kennedy,Eric L. Sievers,Robert T. Chen +17 more
TL;DR: The ADC brentuximab vedotin was associated with manageable toxicity and induced objective responses in 75% of patients with relapsed or refractory HL after autologous stem-cell transplantation (auto-SCT).
Journal ArticleDOI
Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
Barbara Pro,Ranjana H. Advani,Pauline Brice,Nancy L. Bartlett,Joseph D. Rosenblatt,Timothy M Illidge,Jeffrey Matous,Radhakrishnan Ramchandren,Michelle A. Fanale,Joseph M. Connors,Yin Yang,Eric L. Sievers,Dana A. Kennedy,Andrei R. Shustov +13 more
TL;DR: Targeted therapy with this CD30-directed antibody-drug conjugate brentuximab vedotin may be an effective treatment for relapsed or refractory systemic ALCL and warrants further studies in front-line therapy.
Journal ArticleDOI
B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose-escalation trial of rituximab
R. John Looney,Jennifer H. Anolik,Debbie Campbell,Raymond E. Felgar,Faith Young,Lois J. Arend,James A. Sloand,Joseph D. Rosenblatt,Iñaki Sanz +8 more
TL;DR: Rituximab therapy appears to be safe for the treatment of SLE and holds significant therapeutic promise, at least for the majority of patients experiencing profound B cell depletion.
Journal ArticleDOI
Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial.
Judith E. Karp,Jeffrey E. Lancet,Scott H. Kaufmann,David W. End,John J. Wright,Kees Bol,Ivan Horak,Michael L. Tidwell,Jane L. Liesveld,Timothy Kottke,Dawn Ange,Laxmi Narayana Buddharaju,Ivana Gojo,W. Edward Highsmith,Robert T. Belly,Raymond J. Hohl,Mary Ellen Rybak,Alain Thibault,Joseph D. Rosenblatt +18 more
TL;DR: The results of this first clinical trial of a signal transduction inhibitor in patients with acute leukemias suggest that inhibitors of FT may have important clinical antileukemic activity.
Journal ArticleDOI
High Rate of HTLV-II Infection in Seropositive IV Drug Abusers in New Orleans
Helen Lee,Priscilla Swanson,Vernon S. Shorty,Jerome A. Zack,Joseph D. Rosenblatt,Irvin S. Y. Chen +5 more
TL;DR: A sensitive modification of the polymerase chain reaction method was used to provide unambiguous molecular evidence that a significant proportion of intravenous drug abusers are infected with HTLV, and the majority of these individuals are infectedwithHTLV-II rather than HTLV-I.